Regeneron Pharmaceuticals Inc. buy DerAlmanach100000
Start price
11.05.26
/
100%
€609.80
Target price
11.05.29
-
Performance (%)
7.74%
End price
05.08.26
€657.00
Summary
This prediction ended on 05.08.26 with a price of €657.00. The BUY prediction by DerAlmanach100000 finished with a performance of 7.74%. A total of €0.94 was paid as dividends for this prediction. DerAlmanach100000 has 100% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
AI-generated
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Regeneron Pharmaceuticals Inc. | 2.524% | 2.524% |
| iShares Core DAX® | 2,57 % | 5,33 % |
| iShares Nasdaq 100 | 4,86 % | 0,45 % |
| iShares Nikkei 225® | 5,59 % | -0,59 % |
| iShares S&P 500 | 3,25 % | 2,50 % |
According to DerAlmanach100000 what are the pros and cons of Regeneron Pharmaceuticals Inc. for the foreseeable future?
Pros
Could be very worthwhile Investment >20% year